Research
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
BMJ 2017; 359 doi: https://doi.org/10.1136/bmj.j4530 (Published 04 October 2017) Cite this as: BMJ 2017;359:j4530
Data supplement
Web Extra
- Data Supplement - Appendix: Supplementary material
Related articles
- Editorial Published: 04 October 2017; BMJ 359 doi:10.1136/bmj.j4528
- Feature Published: 04 October 2017; BMJ 359 doi:10.1136/bmj.j4543
- Editorial Published: 26 February 2018; BMJ 360 doi:10.1136/bmj.k840
- Analysis Published: 17 May 2018; BMJ 361 doi:10.1136/bmj.k1039
- Analysis Published: 10 July 2019; BMJ 366 doi:10.1136/bmj.l4340
- Editorial Published: 18 September 2019; BMJ 366 doi:10.1136/bmj.l5399
- Research Published: 18 September 2019; BMJ 366 doi:10.1136/bmj.l5221
See more
- Half of trials supporting new cancer drug approval in Europe had high risk of biasBMJ September 19, 2019, 366 l5619; DOI: https://doi.org/10.1136/bmj.l5619
- Cancer survival improves in UK but still lags behind other high income countriesBMJ September 11, 2019, 366 l5508; DOI: https://doi.org/10.1136/bmj.l5508
- Medical cannabis: patients turn to private clinics because of NHS voidBMJ September 02, 2019, 366 l5290; DOI: https://doi.org/10.1136/bmj.l5290
- Offer daily aspirin to cut risk of colorectal cancer in people with Lynch syndrome, says NICEBMJ August 02, 2019, 366 l5010; DOI: https://doi.org/10.1136/bmj.l5010
- Scotland’s breast screening review does not tackle benefit-risk issueBMJ July 31, 2019, 366 l4954; DOI: https://doi.org/10.1136/bmj.l4954
Cited by...
- Flawed evidence underpins approval of new cancer drugs
- Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis
- New drugs: where did we go wrong and what can we do better?
- Ab-initio discovery of tumoricidal oligonucleotides in a DNA sequencing machine
- Discovery of tumoricidal DNA oligonucleotides by effect-directed in-vitro evolution
- On fitness: how do mutations shape the biology of cancer?
- Biomarkers for capturing disease pathology as molecular process hyperstructure
- Premarket evaluation of medical devices: a cross-sectional analysis of clinical studies submitted to a German ethics committee
- Impact of Patient- and Clinician-Reported Cumulative Toxicity on Quality of Life in Patients With Metastatic Castration-Naive Prostate Cancer
- Detection of a novel, primate-specific 'kill switch tumor suppression mechanism that may fundamentally control cancer risk in humans: an unexpected twist in the basic biology of TP53
- Pathways to faster access to medicines
- Choosing wisely in oncology: necessity and obstacles
- Conflict of interest among Italian medical oncologists: a national survey
- Healing an ailing pharmaceutical system: prescription for reform for United States and Canada
- Removing the blindfold on medicines pricing
- Outcomes for cancer drugs approved in Europe
- Cancer drugs: high price, uncertain value
- Do cancer drugs improve survival or quality of life?